Curewin-Hylico Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 31-07-2024
- Paid Up Capital ₹ 3.50 Cr
as on 31-07-2024
- Company Age 10 Year, 16 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.72 Cr
as on 31-07-2024
- Revenue -12.18%
(FY 2023)
- Profit 153.07%
(FY 2023)
- Ebitda 4.15%
(FY 2023)
- Net Worth 70.97%
(FY 2023)
- Total Assets 20.55%
(FY 2023)
About Curewin-Hylico Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company currently has active open charges totaling ₹1.72 Cr.
Srinivas Lagisetty, Babu Julapalli, and Madhavaram Rao serve as directors at the Company.
- CIN/LLPIN
U51101TG2014PTC096702
- Company No.
096702
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Curewin-Hylico Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babu Julapalli  | Director | 12-Apr-2015 | Current |
| Srinivas Lagisetty | Director | 05-Dec-2014 | Current |
| Madhavaram Rao | Director | 28-Apr-2018 | Current |
Financial Performance of Curewin-Hylico Pharma.
Curewin-Hylico Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.18% decrease. The company also saw a substantial improvement in profitability, with a 153.07% increase in profit. The company's net worth Soared by an impressive increase of 70.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curewin-Hylico Pharma?
In 2023, Curewin-Hylico Pharma had a promoter holding of 53.13% and a public holding of 46.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 19 Mar 2022 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 19 Jan 2022 | ₹2.20 M | Open |
Hdfc Bank Limited Creation Date: 04 Sep 2020 | ₹5.00 M | Open |
How Many Employees Work at Curewin-Hylico Pharma?
Curewin-Hylico Pharma has a workforce of 82 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curewin-Hylico Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curewin-Hylico Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
